Head-to-head evidence
dulaglutide vs Supaglutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
dulaglutide · Trulicity
Marketed by Eli Lilly
NCT01394952 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial involving 9,901 participants. The hard clinical primary endpoint was met: 594 dulaglutide participants versus 663 placebo participants experienced a composite cardiovascular event, with a hazard ratio of 0.88 (p=0.026).
Next expected readout: April 2027 · NCT07537088 (registry estimate)
Supaglutide
Developed by Shanghai Yinnuo Pharmaceutical Technology
NCT04998032 · Phase 2/3 · completed
In this randomized, double-blind, placebo-controlled Phase 2b/3 trial in 620 adults with type 2 diabetes already taking metformin, adding once-weekly supaglutide significantly lowered blood-sugar control (HbA1c) at 24 weeks compared with adding placebo, with a clearly significant treatment difference.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: dulaglutide's landscape · Supaglutide's landscape